Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

5.98USD
24 Dec 2014
Price Change (% chg)

$0.01 (+0.17%)
Prev Close
$5.97
Open
$5.95
Day's High
$5.99
Day's Low
$5.75
Volume
322,402
Avg. Vol
951,450
52-wk High
$7.82
52-wk Low
$3.12

OREX.OQ

Chart for OREX.OQ

About

Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the... (more)

Overall

Beta: 2.50
Market Cap (Mil.): $736.53
Shares Outstanding (Mil.): 123.17
Dividend: --
Yield (%): --

Financials

  OREX.OQ Industry Sector
P/E (TTM): -- 149.43 38.63
EPS (TTM): -0.56 -- --
ROI: -60.35 -0.54 18.26
ROE: -261.37 -1.67 19.13
Search Stocks

Orexigen diet pill recommended for approval in Europe

LONDON - A new diet pill from Orexigen Therapeutics Inc has been recommended for approval in Europe, the European Medicines Agency (EMA) said on Friday.

19 Dec 2014

European regulators recommend approval of Orexigen's obesity pill

- European regulators recommended the approval of Orexigen Therapeutics Inc's diet pill, which could become the first prescription medicine for obesity to be approved in the European Union in nearly a decade.

19 Dec 2014

UPDATE 1-European regulators recommend approval of Orexigen's obesity pill

Dec 19 - European regulators recommended the approval of Orexigen Therapeutics Inc's diet pill, which could become the first prescription medicine for obesity to be approved in the European Union in nearly a decade.

19 Dec 2014

European regulators recommend approval of Orexigen's obesity pill

Dec 19 - Orexigen Therapeutics Inc said European regulators recommended the approval of the drugmaker's obesity pill on Friday.

19 Dec 2014

Orexigen diet pill recommended for approval in Europe

LONDON, Dec 19 - A new diet pill from Orexigen Therapeutics Inc has been recommended for approval in Europe, the European Medicines Agency (EMA) said on Friday.

19 Dec 2014

BUZZ-Orexigen Therapeutics Inc: Diet drug launched

** Drugmaker's shares up 20 pct at $4.88, biggest intra-day percentage jump in more than two years

21 Oct 2014

CORRECTED-Long-awaited diet pill gets U.S. approval

(Corrects paragraph 9 to say RS Investments, not RS Investments' value fund, holds a stake in Orexigen. A previous version was corrected to fix Daniel Lang's designation)

11 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks